TRIN Pharma starts phase I clinical trial of TRIN 2755 in solid tumors

| Print |
Tuesday, 10 November 2009 10:00 (UTC + 1)

 TRIN_Logo

Appenzell, Switzerland, November 10, 2009 / b3c newswire / - TRIN Pharma GmbH, specializing in the development of small molecule drugs for tumor treatment, announced today that BfArM, the German regulatory authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumors. The trial will be conducted at two very experienced clinical sites in Germany, Westdeutsches Tumorzentrum in Essen and Tumor Biology Center in Freiburg.

 

TRIN 2755 is based on a new chemistry with solid IP platform. Preclinical experiments have demonstrated excellent activity of TRIN 2755 in xenograft models of human malignant melanoma, breast and colon cancer, including drug resistant tumors. The vast majority of animals treated with TRIN 2755 reached complete and stable remission at well tolerated doses.

 

TRIN 2755, the company's lead molecule in a series of novel triazene analogs, exerts rapid metabolic clearance while at the same time tolerability was very good in early toxicology studies.

 

Stefan Wohlfeil, CEO of TRIN Pharma said: "We are very excited about the start of the clinical development of our lead molecule. We believe that TRIN 2755 has a high likelihood of showing clinical benefit and to become an important part of anti-cancer therapy."


About TRIN Pharma – www.trinpharma.com
TRIN Pharma GmbH develops new small molecule drugs for effective tumor treatment. The research is focused on innovative compounds with proprietary molecular structure, high selectivity and potent anti-tumor activity. TRIN Pharma’s business objective is the development of its molecules into clinical studies and commercialization. TRIN Pharma is financed by High Tech Private Equity, Düsseldorf, Germany.

 

 

Contacts

Dr. Stefan Wohlfeil, MD
Chief Executive Officer
TRIN Pharma GmbH
Rütistrasse 20
CH-9050 Appenzell
Tel.: +41-(0)71-788 4063
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 


Prof. Max Scheulen
Assistant Medical Director
Westdeutsches Tumorzentrum
Tel.: +49 (0) 201-723-3152 or

Tel.: +49 (0) 201-723-3956